Bioengineers at Yale and Cornell have created a modified chemotherapy that more effectively reaches and remains at the site of brain tumors — by adding a water-soluble polymer to the anti-cancer drug, according to a report in the November-December issue of Bioconjugate Chemistry.
Researches at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important “intercept points” for cancer cells.
A non-invasive diagnostic tool to detect surface cancers quickly and painlessly using technology currently employed by gyms to calculate body composition has been developed by a QUT PhD medical physics researcher.
A team of investigators from the Massachusetts General Hospital (MGH) BioMicroElectroMechanical Systems (BioMEMS) Resource Center and the MGH Cancer Center has developed a microchip-based device that can isolate, enumerate and analyze circulating tumor cells (CTCs) from a blood sample. CTCs are viable cells from solid tumors carried in the bloodstream at a level of one in a billion cell. Because of their rarity and fragility, it has not been possible to get information from CTCs that could help clinical decision-making, but the new device - called the "CTC-chip,"- has the potential to be an invaluable tool for monitoring and guiding cancer treatment.
A relatively new, minimally invasive treatment was 100 percent successful in eradicating small malignant kidney tumors in a study of more than 100 patients, report researchers from Wake Forest University Baptist Medical Center.